GBP | G Biological Products:

​

Venom-Based Cancer Research Services

Exclusive For Your VENOM

 

Validating Venom’s Therapeutic Potential for the Health & Pharma Markets

​

Introduction

At GBP | G Biological Products, we bridge toxinology and oncology through cutting-edge research, demonstrating how scorpion and snake venoms can target and disrupt 8 high-impact cancer types. Our certified lab services empower venom producers, biotech firms, and pharmaceutical partners with scientific validation, enhancing product credibility for therapeutic, nutraceutical, or diagnostic applications.

​

Our Research Process: From Venom to Validation

 

1. Client-Specific Venom Profiling

• Step 1: Clients submit purified venom samples (species-specific, e.g., Androctonus crassicauda or Naja pallida).

• Step 2: GBP’s team conducts HPLC/MS analysis to fingerprint bioactive compounds (e.g., chlorotoxin, disintegrins).

• Deliverable: A detailed biochemical report linking venom peptides to known anticancer mechanisms.

​

​

2. In Vitro Screening Against 8 Cancer

Types

 

We test venom efficacy on cancer cell lines, including:

1. Breast adenocarcinoma (MCF-7)

2. Glioblastoma (U87-MG)

3. Pancreatic cancer (PANC-1)

4. Lung carcinoma (A549)

5. Prostate cancer (PC-3)

6. Colorectal cancer (HCT-116)

7. Ovarian cancer (SK-OV-3)

8. Melanoma (A375)

Methodology:

• Cell viability assays (MTT/XTT) to measure venom-induced apoptosis.

• Migration/invasion tests to assess metastatic inhibition.

• Synergy studies with conventional chemo drugs (e.g., Venom + Cisplatin).

Deliverable: A dose-response curve and IC50 values for each cancer type, proving therapeutic potential.

​

​

3. Mechanistic Studies (Optional Premium Service)

​

• Molecular docking to identify venom-protein interactions (e.g., Matrix metalloproteinase inhibition).

• Gene expression analysis (qPCR/RNA-Seq) to uncover pathways like p53 activation or NF-κB suppression.

• Deliverable: A publication-ready dossier for client R&D or investor pitches.

​

​

4. In Vivo Validation (Collaborative Tier)

​

• Xenograft mouse models treated with client’s venom-derived peptides.

• Toxicity & efficacy metrics (tumor volume reduction, survival rates).

• Deliverable: Preliminary data for FDA preclinical filings or IP patents.

​

​

Why Partner with GBP for Venom-Cancer Research?

 

1. Credibility for Your Venom Products

• Turn raw venom into a data-backed therapeutic candidate with GBP’s peer-recognized assays.

• Case Study: A client’s Leiurus quinquestriatus venom showed 60% glioblastoma cell death—leveraged to secure $2M in biotech funding.

​

​

2. Market Differentiation

​

• Our reports help clients label products as “scientifically validated” for:

  • Nutraceuticals (e.g., “Venom peptides support cellular health”).

  • Cosmeceuticals (antimetastatic claims for topical formulations).

  • Diagnostic tools (tumor-targeting venom biomarkers).

​​

​

3. Regulatory & Commercial Support

• GLP-compliant data for IND applications.

• White-label research services to brand findings under your client’s name.

​

Sample Client Success Pathway

​

1. Client Submits Tityus serrulatus venom.

2. GBP Identifies potent β-toxins blocking pancreatic cancer glycolysis.

3. Client Markets venom as “Oncologically Active Ingredient” with GBP-certified data.

4. Result: 300% markup in B2B venom sales + pharma licensing deals.

​

​

Call to Action

For venom producers & biotech innovators:
Let GBP transform your venom into a scientifically validated, high-value health product.

​

Service Tiers:​

• Comprehensive Oncology Report ($60.000) : Full 8-cancer panel + mechanistic insights.

• Premium Partnership: Custom in vivo studies & IP support.

​

​